drugset / Trial / NCT00392678

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

NCT00392678

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. The first stage is a dose ranging study, administering salsalate compared to placebo over three months. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. The second stage is a second trial and posted under alternate registration.

Timeline

Start
2006-10
Primary completion
2008-07
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salsalate Small molecule 3 g Oral
Comparator Salsalate Small molecule 3.5 g Oral
Comparator Salsalate Small molecule 4 g Oral